News & Updates

$Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis$

Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis

24 Dec 2023 by

Fedratinib is superior to the best available therapy (BAT) in terms of spleen volume reduction (SVR) and symptom response rates in patients with myelofibrosis (MF) treated with the Janus kinase inhibitor (JAKi) ruxolitinib, as shown in a study presented at ASH 2023.

Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis

24 Dec 2023

Faecal matter transplant exerts no beneficial effect on cardiometabolic risk factors

23 Dec 2023

Faecal microbiota transplantation (FMT) does not appear to have any significant effect on the cardiometabolic parameters of individuals with at least one cardiometabolic issue, according to the results of a systematic review and meta-analysis.

Faecal matter transplant exerts no beneficial effect on cardiometabolic risk factors

23 Dec 2023

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

23 Dec 2023

Treatment with metformin plus insulin early in pregnancy for women with pre-existing type 2 diabetes (T2D) or gestational diabetes falls short of reducing the risk of adverse neonatal outcomes, as shown in the MOMPOD study.

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

23 Dec 2023

Etranacogene dezaparvovec safe, effective for haemophilia B patients with HIV

23 Dec 2023 by

Treatment with etranacogene dezaparvovec demonstrates efficacy with a favourable safety profile in a subset of adult patients with severe or moderately severe haemophilia B living with HIV, according to a recent study presented at ASH 2023.

Etranacogene dezaparvovec safe, effective for haemophilia B patients with HIV

23 Dec 2023

No apparent harm seen with early pregnancy ozanimod exposure, but caution still urged

23 Dec 2023 by

Exposure to ozanimod during early pregnancy does not appear to pose risks of adverse pregnancy outcomes and foetal health despite recommendations to avoid getting pregnant while receiving ozanimod and for 3 months after treatment discontinuation, according to a study.

No apparent harm seen with early pregnancy ozanimod exposure, but caution still urged

23 Dec 2023

Low-dose naltrexone in fibromyalgia: No pain relief, but memory boost possible

22 Dec 2023

In the treatment of individuals with fibromyalgia, low-dose naltrexone does not appear to help reduce pain but might improve memory instead, as reported in a study.

Low-dose naltrexone in fibromyalgia: No pain relief, but memory boost possible

22 Dec 2023

Does appendix removal raise risk of Crohn’s disease?

22 Dec 2023 by

Individuals who have undergone an appendectomy may be at heightened risk of Crohn’s disease, according to the results of a systematic review and meta-analysis.

Does appendix removal raise risk of Crohn’s disease?

22 Dec 2023

Should KD patients be screened for Yersinia infection?

22 Dec 2023

Routine screening for Yersinia infection is not recommended for patients with Kawasaki disease (KD), suggests a recent study.

Should KD patients be screened for Yersinia infection?

22 Dec 2023

First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma

22 Dec 2023 by

First-line combination immuno-oncology therapy (IO) with ipilimumab and nivolumab provides beneficial effects and has an acceptable safety profile in patients with metastatic renal cell carcinoma, as shown in a Japan study presented at ESMO Asia 2023.

First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma

22 Dec 2023

Liquid NGS helps prolong survival in patients with advanced solid tumours

22 Dec 2023 by

Patients with advanced solid tumours who have been treated according to matched targetable genomic mutation exhibit significantly longer overall survival than those who received standard-of-care (SOC) treatment, according to a Philippines study presented at ESMO Asia 2023.

Liquid NGS helps prolong survival in patients with advanced solid tumours

22 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis

Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis

Faecal matter transplant exerts no beneficial effect on cardiometabolic risk factors

Faecal matter transplant exerts no beneficial effect on cardiometabolic risk factors

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

Etranacogene dezaparvovec safe, effective for haemophilia B patients with HIV

Etranacogene dezaparvovec safe, effective for haemophilia B patients with HIV

No apparent harm seen with early pregnancy ozanimod exposure, but caution still urged

No apparent harm seen with early pregnancy ozanimod exposure, but caution still urged

Low-dose naltrexone in fibromyalgia: No pain relief, but memory boost possible

Low-dose naltrexone in fibromyalgia: No pain relief, but memory boost possible

Does appendix removal raise risk of Crohn’s disease?

Does appendix removal raise risk of Crohn’s disease?

Should KD patients be screened for Yersinia infection?

Should KD patients be screened for Yersinia infection?

First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma

First-line ipilimumab plus nivolumab delivers benefits in metastatic renal cell carcinoma

Liquid NGS helps prolong survival in patients with advanced solid tumours

Liquid NGS helps prolong survival in patients with advanced solid tumours